Skip to content
Open access

PRKN-independent mitophagy regulators in dopaminergic neurons identified by genome-wide CRISPR screening.

Nov 2026 · Neurosciences research · pp. 105154 · 0 citations · 36 references
Medicine

Abstract

Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Genetic and epidemiological studies have suggested that mitochondrial dysfunction is implicated in the development of PD. PRKN/Parkin is known to play an essential role in mitochondrial quality control and mitophagy. Indeed, mutations and inactivation of this gene are associated with hereditary and idiopathic forms of PD. Despite extensive studies on PRKN-dependent mitophagy, the molecular regulators of PRKN-independent mitophagy in dopaminergic neurons remain incompletely understood. We generated a PRKN knockout iPSC-derived dopaminergic neuronal line expressing the fluorescent mitophagy biosensor mito-SRAI, which reports the delivery of mitochondria to lysosomes as an increase in the TOLLES/YPet fluorescence ratio. We used this cell line to conduct a genome-wide CRISPR knockout screen to reveal genetic regulators involved in PRKN-independent mitophagy. Dozens of genes were identified whose knockout increased the TOLLES/YPet ratio in an uncoupler-dependent manner. Of these, several genes emerged as candidates with potential therapeutic implications, one of which was Cathepsin F (CTSF). CCCP treatment increased the TOLLES/YPet ratio in neurons with siRNA-mediated CTSF knockdown, and CTSF knockdown partially preserved the proportion of tyrosine hydroxylase-positive dopaminergic neurons after paraquat exposure. These results suggest that CTSF is a candidate regulator of PRKN-independent mitophagy and that this lysosomal enzyme may represent a potentially druggable candidate target for PD.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.